Immunicom Secures $11 Million in Series B Investment Round

SAN DIEGO, July 2, 2019 -- (Healthcare Sales & Marketing Network) -- Immunicom, Inc., a biotechnology company awarded FDA Breakthrough Device Designation for its non-pharmaceutical solution for treating late-stage metastatic cancer, raised $11 million in ... Devices, Venture Capital Immunicom, immunotherapy, Immunopheresis, blood filtering
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news